Previous 10 | Next 10 |
The following slide deck was published by Ayala Pharmaceuticals, Inc. in conjunction with this event. For further details see: Ayala Pharmaceuticals Inc (AYLA) Investor Presentation - Slideshow
Eli Lilly reports positive data for Phase 3 monarchE trial. Soligenix gets boost from Filovirus vaccine antigens data. Ayala Pharmaceuticals posts encouraging interim data for AL101. For further details see: Eli Lilly Reports MonarchE Data, And Other News: The Good, Bad ...
Ayala Pharmaceuticals ( AYLA -10.2% ) has announced interim data from the ongoing Phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations. Data were presented at the European Society for Medi...
– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate - Company to host virtual KOL event to review data today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del., Sept. 18, 2020 (GLOBE NEWSW...
Gainers: Ebang International (NASDAQ: EBON ) +42% . More news on: Ebang International Holdings Inc., Cardiff Oncology, Inc., Herman Miller, Inc., Stocks on the move, , Read more ...
REHOVOT, Israel and WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in ...
Gainers: PolyMet Mining (NYSEMKT: PLM ) +83% . More news on: PolyMet Mining Corp., VivoPower International PLC, FBL Financial Group, Inc., Stocks on the move, , Read more ...
REHOVOT, Israel and WILMINGTON, Del., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (the Company or Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggres...
Ayala Pharmaceuticals (NASDAQ: AYLA ) : Q2 GAAP EPS of -$0.74 misses by $0.21 . More news on: Ayala Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– New interim data from Phase 2 ACCURACY study of AL101 for the treatment of R/M ACC to be presented at ESMO 2020 – – On track to initiate patient dosing in Phase 2 TENACITY study of AL101 for the treatment of TNBC in 2020 – REHOVOT, Israel ...
News, Short Squeeze, Breakout and More Instantly...
Ayala Pharmaceuticals Inc. Company Name:
AYLA Stock Symbol:
NASDAQ Market:
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Societ...
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmace...